Name:Advanced glycosylation end product-specific receptor Target Synonym:Receptor for advanced glycosylation end products,AGER,Advanced Glycosylation End-Product Specific Receptor,RAGE,Receptor For Advanced Glycation End-Products Variant 20,Receptor For Advanced Glycation End-Products,RAGE Isoform NtRAGE-Delta,RAGE Isoform SRA
Number of Launched Drugs:0 Number of Drugs in Clinical Trials:3 Lastest Research Phase:Phase 3 Clinical
Synonym Name
AGER,RAGE
Background
Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.
A-Z
